Bank of New York Mellon Corp raised its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 1.7% in the second quarter, HoldingsChannel reports. The firm owned 836,992 shares of the company’s stock after buying an additional 13,824 shares during the quarter. Bank of New York Mellon Corp’s holdings in Vir Biotechnology were worth $20,531,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in VIR. Signaturefd LLC grew its position in shares of Vir Biotechnology by 1,313.0% during the first quarter. Signaturefd LLC now owns 1,300 shares of the company’s stock worth $30,000 after purchasing an additional 1,208 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Vir Biotechnology by 33.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $42,000 after buying an additional 456 shares during the last quarter. Tucker Asset Management LLC purchased a new position in shares of Vir Biotechnology in the first quarter worth $46,000. Captrust Financial Advisors boosted its position in shares of Vir Biotechnology by 1,270.7% during the second quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock worth $46,000 after acquiring an additional 1,690 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Vir Biotechnology by 97.4% during the first quarter. Fifth Third Bancorp now owns 2,169 shares of the company’s stock valued at $50,000 after acquiring an additional 1,070 shares in the last quarter. Hedge funds and other institutional investors own 67.05% of the company’s stock.
Vir Biotechnology Price Performance
Vir Biotechnology stock opened at $8.79 on Monday. The firm has a market capitalization of $1.18 billion, a P/E ratio of -1.96 and a beta of 0.31. Vir Biotechnology, Inc. has a 1-year low of $7.72 and a 1-year high of $31.55. The company’s 50-day moving average is $9.17 and its 200 day moving average is $16.79.
Wall Street Analyst Weigh In
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Five stocks we like better than Vir Biotechnology
- Investing in the Best Airline Stocks
- MarketBeat Week in Review – 11/6 – 11/10
- What is the Shanghai Stock Exchange Composite Index?
- Data giants MongoDB and Snowflake just got upgraded
- What is a Low P/E Ratio and What Does it Tell Investors?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.